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Abstract 
Objectives. The aim of the study was to establish the risk of liver toxicity in HIV/hepatitis C virus (HCV)-
coinfected patients receiving etravirine, according to the degree of liver fibrosis. 
Methods. A prospective cohort study of 211 HIV-infected patients initiating an etravirine-containing regimen 
was carried out. HCV coinfection was defined as a positive HCV RNA test, and baseline liver fibrosis was 
assessed by transient elastography. Hepatotoxicity was defined as clinical symptoms, or an aspartate 
aminotransferase (AST) or alanine aminotransferase (ALT) value > 5-fold higher than the upper limit of 
normal if baseline values were normal, or 3.5-fold higher if values were altered at baseline. 
Results. Overall, 145 patients (69%) were HCV coinfected, with a lower nadir (165 versus 220 cells/μL, 
respectively; p = 0.03) and baseline (374 versus 498 cells/μL, respectively; p = 0.04) CD4 count than 
monoinfected patients. Etravirine was mainly used with two nucleoside reverse transcriptase inhibitors (129; 
61%) or with a boosted protease inhibitor (PI) (28%), with no significant differences according to HCV 
serostatus. Transient elastography in 117 patients (81%) showed a median (range) stiffness value of 8.25 
(3.5–69) kPa, with fibrosis stage 1 in 43 patients (37%) and fibrosis stage 4 in 28 patients (24%). During an 
accumulated follow-up time of 449.3 patient-years (median 548 days), only one patient with advanced 
fibrosis (50.8 kPa) had grade 3–4 liver toxicity (0.7%). Transaminases changed slightly, with no significant 
differences compared with baseline fibrosis, and nine and six patients had grade 1 and 2 transaminase 
increases, respectively. Also, HCV coinfection was not associated with a higher risk of discontinuation (25% 
discontinued versus 21% of monoinfected patients; p = 0.39, log-rank test) or virological failure (8% versus 
12%, respectively; p = 0.4). 
Conclusions. Our data suggest that etravirine is a safe option for HIV/HCV-coinfected patients, including 
those with significant liver fibrosis. 
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Introduction 
Etravirine (ETR), a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), 
has demonstrated good tolerability and efficacy in treatment-naïve and experienced patients [1,2]. 
In those studies, discontinuations because of adverse events were rare, representing less than 10% 
of cases. In particular, there was a low incidence of grade 3–4 transaminase elevation and drug 
discontinuation because of liver-related adverse events, which were reported in 3% and 8% of 
patients, respectively [1,2]. However, data on liver safety in HIV/hepatitis C virus (HCV) 
coinfection were limited, as in both studies no more than 11% and 13% of patients were HCV 
coinfected, respectively, and patients with advanced liver disease are excluded from clinical trials. 
 
Thus, the risk of liver toxicity in HIV/HCV-coinfected patients receiving ETR in the clinical 
setting is not fully established. It is particularly important to establish this risk, given that HCV 
coinfection is the most consistent risk factor for antiretroviral-associated hepatotoxicity [3]. 
Previous studies with other drugs of the same class have shown an incidence of liver toxicity of 3–
20%, with nevirapine having a higher risk than efavirenz in coinfected patients [4]. 
 
Furthermore, the risk of liver toxicity in coinfected patients with significant fibrosis or 
cirrhosis receiving ETR has not been established. Our group has previously demonstrated that the 
degree of liver fibrosis determines the risk of developing liver toxicity. Thus, the use of nevirapine 
or a ritonavir-boosted protease inhibitor (PI/r) was associated with different rates of toxicity 
according to whether mild or severe liver fibrosis was present [5]. 
 
Therefore, it is necessary to determine the risk of hepatotoxicity with the use of a new NNRTI 
such as ETR in HIV/HCV-coinfected patients with different grades of liver fibrosis in the clinical 
setting, this is important, as ETR has become an option for patients who need anti-HCV therapy 
[6]. In addition, patients coinfected with HIV/HCV also are more likely to discontinue therapy 
because of toxicity [7]. 
 
Thus, the primary aim of this study was to determine the liver safety of highly active 
antiretroviral therapy (HAART) including ETR in HIV/HCV-coinfected patients, considering the 
stage of liver fibrosis, in terms of both liver enzyme elevation and regimen discontinuation, in 
comparison with patients without HCV infection. 
Methods 
This was a prospective cohort study that included patients attending two different specialized 
HIV units. Since 2010, patients initiating treatment with ETR were included if they met the 
following criteria: (i) initiation of antiretroviral therapy (ART) that included ETR; (ii) age > 18 
years; and (iii) demonstration of the presence (or absence) of chronic HCV infection as confirmed 
by HCV RNA in serum by polymerase chain reaction (PCR). Patients were excluded if they had 
other liver diseases, or alcohol consumption > 50 g/day. Clinical visits and blood tests were carried 
out at baseline, at month 1, at month 3 and every 3 months thereafter. The study was designed and 
performed according to the Helsinki declaration and was approved by the Ethics Committee of our 
hospital (EC 150/06). 
 
Patients were followed up until the end of July 2014, ETR discontinuation, or the development 
of liver toxicity, whichever occurred first. For patients who started treatment for HCV infection 
during follow-up, the date of end of follow up was the beginning of interferon-based therapy, since 
it was assumed a change in the risk of developing toxicity [8]. 
 
Changes in transaminase levels were classified using the Division of AIDS grading table [9]. 
Thus, in patients with normal baseline levels of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST), values of ALT or AST 5–10 times the upper limit of normal (ULN) were 
considered to indicate liver toxicity grade 3, while grade 4 was defined as ALT or AST values 10 
times the ULN. When patients presented an increased baseline ALT or AST level, an elevation of 
between 3.5- and 5-fold was considered to indicate liver toxicity grade 3, and an elevation > 5-fold 
to indicate grade 4. Bilirubin levels were not considered in the definition of toxicity. 
 
Baseline liver fibrosis was assessed using hepatic transient elastography (FibroScan®; 
Echosense, Paris, France). Briefly, the stiffness of the liver tissue was determined by ultrasound in 
the morning, after an overnight fast, as has been previously described [10]. According to Castera 
et al. [11], we classified liver fibrosis using a stiffness cutoff of 7.2 kPa for fibrosis stage 2, 9.5 kPa 
for fibrosis stage 3, and 12.5 kPa for fibrosis stage 4. For example, this cutoff value of 12.5 kPa 
had a positive and negative predictive value of 77% and 95%, respectively, for the diagnosis of 
fibrosis stage 4 or cirrhosis. 
 
The primary endpoint was hepatotoxicity, as defined above. The secondary outcomes were 
changes in transaminase levels and rate of discontinuation, according to HCV coinfection and liver 
fibrosis. 
 
Continuous variables were analysed using Student's t-test for normal distributions and the 
Mann–Whitney U-test otherwise. Categorical variables were analysed with the χ2 test or Fisher's 
test, where applicable. For repeated transaminase measurements, the Wilcoxon signed rank test for 
continuous measurements was applied. The Kaplan-Meier method was used to assess the rate of 
discontinuation, and the influence of HCV coinfection was assessed using the log-rank test. All P-
values < 0.05 were considered statistically significant. 
Results 
Overall, 211 patients received an ETR-based regimen and were included in the study. Of these, 
145 (69%) were HCV coinfected. The baseline characteristics of all patients and those with HCV 
infection are shown in Table 1. As expected, HCV-coinfected patients had a higher prevalence of 
former injecting drug use as a risk practice and a longer time on HAART. Patients were followed 
for a median time of 548 days (interquartile range 256–1128 days). During follow-up, 50 patients 
(24%) discontinued ETR, in 20 cases because of virological failure. Mild or moderate rash was 
observed in 12 patients, five of whom discontinued ETR. The rate of discontinuation in the group 
of HCV-coinfected patients was similar to that in HCV-uninfected patients (25 versus 21%; 
P = 0.39; log-rank test). 
  
Table 1. Baseline characteristics of patients according to HIV/hepatitis C virus (HCV) coinfection 
Variable 
Overall 
(n = 211) 
HIV/HCV coinfection 
(n = 145; 69%) 
HIV monoinfected 
(n = 66; 31%) 
P-value 
Age (years) [mean (range)] 44 (32–68) 48 (36–68) 42 (28–55) 0.09 
Sex male [n (%)] 143 (68) 93 (64) 50 (76) 0.16 
Former IDU [n (%)] 133 (63) 130 (90) 3 (5) <0.01 
Nadir CD4 count (cells/μL) [median 
(IQR)] 
185 (97–287) 165 (88–252) 220 (97–349) 0.03 
Time on HAART prior to ETR (months) 
[median (IQR)] 
155.3 (52.7–
167.8) 
166.3 (112–197) 57.4 (9.7–140.3) <0.01 
CD4 count at inclusion (cells/μL) [median 
(IQR)] 
400 (221–678) 374 (215–672) 498 (269–770) 0.04 
HIV RNA level ≤ 50 copies/mL at 
inclusion [n (%)] 
137 (65) 85 (59) 52 (79) 0.03 
ETR plus [n (%)]: 
    
2 NRTIs 129 (61) 89 (61) 40 (60) 
 
PI/r 39 (19) 27 (19) 12 (18) 0.7 
PI/r + RTG 20 (9) 13 (9) 7 (11) 
 
RTG ± NRTI 23 (11) 16 (11) 7 (11) 
 
Reasons for ETR initiation [n (%)] 
   
0.29 Toxicity/intolerance 141 (67) 93 (64) 48 (73) 
Virological failure 70 (33) 52 (36) 18 (27) 
Virological failure with ETR [n (%)] 20 (10) 12 (8) 8 (12) 0.45 
Rash with ETR [n (%)] 12 (6) 7 (5) 5 (8) 0.2 
ETR discontinuation [n (%)] 50 (24) 36 (25) 14 (21) 0.6 
Time on ETR (days) [median (IQR)] 
548 (256–
1128) 
502 (233–925) 673 (317–1292) 0.1 
Transient elastography at baseline [n 
(%)]*     
Fibrosis stage 1 
 
43 (37) 
  
Fibrosis stage 2 
 
29 (25) 
  
Fibrosis stage 3 
 
17 (14) 
  
Fibrosis stage 4 
 
28 (24) 
  
     
 
*Available in 117 HIV/HCV-coinfected patients. 
IDU, injecting drug use; IQR, interquartile range; HAART, highly active antiretroviral therapy; ETR, etravirine; NRTI, 
nucleoside reverse transcriptase inhibitor; PI/r, protease inhibitor boosted with ritonavir; RTG, raltegravir; TE, transient 
elastography. 
ETR was used with two nucleoside reverse transcriptase inhibitors (NRTIs) in 61% of patients 
(129 patients: tenofovir plus emtricitabine in 90 patients, and abacavir plus lamivudine in 39 
patients), with a boosted PI (mostly darunavir) in 19%, with darunavir plus raltegravir in 9%, and 
with raltegravir ± one NRTI (PI-sparing regimen) in 11% (23 patients). 
 
During an accumulated follow-up time of 449.3 patient-years, only one patient, who had 
fibrosis stage 4 (stiffness value 50.8 kPa) and started a regimen with tenofovir/emtricitabine plus 
ETR plus darunavir/ritonavir, developed liver toxicity grade 3–4 (0.7%). Transaminase (ALT 
value) changes for mono- and coinfected patients are shown in Fig. 1a. Also, there were six and 
nine cases of grade 2 and 1 transaminase elevations, respectively, in the HCV-coinfected 
population. 
  
 
 
 
Figure 1. Changes in alanine aminotransferase (ALT) concentration during the first year after etravirine 
initiation (at baseline and months 3, 6 and 12), according to (a) hepatitis C virus (HCV) serostatus and (b) 
the degree of liver fibrosis. CI, confidence interval. 
Liver fibrosis measurements obtained by transient elastography were available in 117 patients 
(81% of HCV-coinfected patients). The median (range) stiffness value was 8.25 (3.5 − 69) kPa. 
Fibrosis stage 4 was observed in 24% of patients (28 patients), with 37% of patients having 
fibrosis stage 1. Transaminase changes according to liver fibrosis stage were not significant 
(Fig. 1b). In patients with cirrhosis, there were no hepatic decompensations or other liver-related 
complications during the follow-up period. Discontinuation was similar according to liver fibrosis 
stage (19, 20, 27 and 21% for fibrosis stages 1 to 4, respectively; P = 0.3).  
Discussion 
This cohort study is the largest to investigate, in a clinical setting, the risk of liver toxicity with 
ETR in HIV-infected patients with chronic HCV coinfection. We found that the risk of toxicity 
was low. This finding was obtained irrespective of the degree of liver fibrosis and other drugs 
present in the regimen. There were few changes in transaminases among HIV/HCV-coinfected 
patients after starting an ETR-based regimen, and transaminase values in most patients remained 
within the baseline range observed before initiation of treatment with ETR. 
 
This low incidence of liver toxicity contrasts with that observed in HIV/HCV-coinfected 
patients receiving HAART in previous studies. Even in patients receiving other well-tolerated 
drugs, such as raltegravir or maraviroc, liver events were observed in 5–10% of patients [12,13], 
and a higher rate was found in patients receiving nevirapine-, efavirenz- or PI/r-based regimens 
[14]. Liver safety analyses for PI/r in clinical trials in HIV/HCV-coinfected patients have shown 
an incidence of grade 3–4 transaminase elevations of between 6 and 15%. 
 
Our data are in accordance with those obtained in a subgroup analysis of the DUET studies, 
including only patients with HCV coinfection, in which liver toxicity in the ETR arm was similar 
to that observed in the placebo arm [15]. More recently, in a similar study in a clinical setting, 
Lopez-Cortés et al. [16] reported no cases of liver toxicity grade 3–4 in 103 patients with chronic 
HCV infection receiving ETR plus two NRTIs, and <1% of patients with grade 2 increases in 
transaminases. 
 
Importantly, the discontinuation rate among HIV/HCV-coinfected individuals starting HAART 
ranged from 4 to 13% for PI/r- or nonnucleoside reverse transcriptase inhibitor (NNRTI)-based 
regimens. In a recent study, Grint et al. reported a 44% increased risk of antiretroviral drug 
discontinuation for HCV viraemic patients, and an even higher (59%) increased risk for patients 
receiving NNRTIs, mostly nevirapine or efavirenz [7]. A hyaluronic acid concentration 
of > 100 ng/mL, a marker of liver fibrosis, was associated with a 37% increased risk of 
antiretroviral drug discontinuation. In our study, the rate of discontinuation was not increased in 
HCV-coinfected patients receiving ETR, even when only patients with a more accurate 
determination of advanced fibrosis, obtained using transient elastography, were considered. 
 
In addition, liver fibrosis did not increase significantly the rate of toxicity. The presence of 
cirrhosis may cause metabolic alterations and lead to overexposure to antiretroviral drugs. Our 
results suggest that ETR can be considered relatively safe in patients with cirrhosis. Only one 
coinfected patient with advanced cirrhosis starting a regimen with ETR plus boosted darunavir had 
toxicity. However, the stiffness cutoff value used for cirrhosis was low (12.5 kPa), a threshold that 
provides a high negative predictive value (95%) but a relatively low positive predictive value 
(77%). Thus, although some of our patients with fibrosis stage 4 or cirrhosis could be classified as 
having fibrosis stage 3 if a different criterion is used [17], most of our patients had moderate or 
advanced liver fibrosis (63% had fibrosis stage 2 or higher). 
 
The underlying reason for this low risk of hepatotoxicity has not been fully established. In a 
phase I pharmacokinetic study, no clinically relevant differences were observed between patients 
with mild or moderate hepatic impairment and healthy matched HIV-negative subjects with regard 
to the pharmacokinetics of ETR, and no dose adjustment of ETR was necessary in patients with 
mild or moderate hepatic impairment [18]. Also, ETR oral clearance seemed not to be affected by 
hepatitis B virus coinfection in a pharmacokinetic study, and no relationship was found between 
ETR pharmacokinetics and either efficacy or safety [19]. However, ETR produces lower hepatic 
cell induction than other NNRTIs, a fact that could explain our results [20]. 
 
This low risk of hepatotoxicity could permit the safe use of ETR while patients are on HCV 
therapy including drugs such as telaprevir, since the concomitant use of both drugs has been 
demonstrated to be safe and effective previously [6]. However, there are few data about drug – 
drug interactions between ETR and new anti-HCV agents. In vivo, ETR is a substrate for, and a 
weak inducer of, the hepatic cytochrome P450 (CYP) isoenzyme 3A4 and a substrate and weak 
inhibitor of CYP2C9 and CYP2C19. Also, it is a weak inhibitor of P-glycoprotein (P-gp) [19]. 
Thus, hypothetically, ETR could decrease levels of some new HCV NS3/4a protease inhibitors 
(simeprevir, paritaprevir, asunaprevir and grazoprevir), NS5A inhibitors (daclatasvir, ombutasvir 
and elbasvir) and NS5B inhibitors (dasabuvir), which are metabolized by CYP3A4 and/or 
transported by P-gp [21]. However, sofosbuvir and ledipasvir are not influenced by a potent 
CYP3A4 inducer such as efavirenz, and daclatasvir requires only increased doses. Therefore, our 
knowledge about interactions between ETR and anti-HCV agents needs to be improved. 
 
The main limitation of our study is the cohort design. Thus, there are no comparative data on 
the use of other drugs in the same patients which could put into perspective the risk of ETR use. 
Furthermore, visits are more frequent in clinical trials, allowing the detection of more laboratory 
abnormalities. However, patients were followed in a clinical schedule. It is therefore unlikely that 
the prevalence of clinically relevant hepatotoxic events was underestimated. In addition, fibrosis 
assessment was not possible in all HCV-coinfected patients. However, nearly 90% of HCV-
coinfected patients could be classified in terms of fibrosis, and can therefore be regarded as 
representative of the whole study population. Finally, fibrosis was assessed using transient 
elastography, not liver biopsy. Nevertheless, it has been demonstrated that there is a high 
correlation between liver biopsy and transient elastometry results [10]. 
 
In conclusion, the liver tolerance of ETR in HIV/HCV-coinfected patients in real-life 
conditions of use was high, even in patients with significant liver fibrosis. Therefore, ETR seems 
to be a safe option for coinfected patients. 
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